(AJMC.org) BEING DIAGNOSED WITH CANCER is often the scariest news a patient will hear in his or her lifetime. In addition to the physical toll of the disease itself, there are numerous other factors associated ...
(OncLive) Immuno-oncology (I/O) drugs have the potential to improve the level of care in many respects, but they bring with them a host of problems related to implementation that require a completely new ...
(ASCO Post) Lee S. Schwartzberg, MD, of The West Clinic, reports on progress of the now year-old ACCC initiative to speed adoption of immunotherapeutics in community practices from the 2016 ASCO Annual ...
(Endpoints News) May 25, 2017 - MPM founded Harpoon Therapeutics and seeded its early work looking to make the leap into next-gen immuno-oncology drugs with some insights from one of the pioneers in the field.
(Fred Hutch News Service) May 25, 2017 - Since 2009, the Bezos family has donated and leveraged more than $40 million to Fred Hutchinson Cancer Research Center in support of immunotherapy research, which harnesses the power of the immune system to kill cancer.
(AstraZeneca) May 26, 2017 - Investigational data for Lynparza™ (olaparib) tablets in BRCA-mutated metastatic breast cancer to be highlighted in plenary presentation of Phase III OlympiAD trial; key investigational trials show further evidence of Tagrisso® (osimertinib) effect in patients with EGFR T790M mutation-positive non-small cel...
(UCLA/Jonsson CCC) May 25, 2017 - A new study by UCLA scientists has found that the breakthrough immunotherapy drug pembrolizumab can be more effective in improving survival in people with non-small cell lung cancer (NSCLC) if they have previously received radiation therapy, compared to those without a history of radiation treatment.
(Targeted Oncology) May 23, 2017 - The recent explosion of FDA approvals in the field of urothelial carcinoma, first and foremost, offers patients options for subsequent lines of therapy, says Peter Black, MD. However, it also raises the question of which of these 5 immunotherapy agents physicians should use.
(BMS) May 24, 2017 - Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) accepted a supplemental Biologics License Application (sBLA) that seeks to extend the use of Opdivo (nivolumab) to patients with hepatocellular carcinoma (HCC) after prior sorafenib therapy.
(Forbes) May 23, 2017 - The FDA’s accelerated approval of this drug might surprise traditional oncologists. It suggests the agency may be ditching an archaic system for classifying cancers based on body parts—like breast or liver or colon cancer—and instead will focus on molecular aspects of malignancies.
Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response.
Cancer Res. 2017 May 01;77(9):2318-2327
Authors: Larimer BM, Wehrenberg-Klee E, Dubois F, Mehta A, Kalomeris T, Flaherty K, Boland G, Mahmood U
While cancer immunotherapy can produce dr...
Targeting autocrine CCL5-CCR5 axis reprograms immunosuppressive myeloid cells and reinvigorates antitumor immunity.
Cancer Res. 2017 Apr 17;:
Authors: Ban Y, Mai J, Li X, Mitchell-Flack M, Zhang T, Zhang L, Chouchane L, Ferrari M, Shen H, Ma X
Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment.
J Natl Cancer Inst. 2017 Apr 01;109(4):
Authors: Gulley JL, Madan RA, Pachynski R, Mulders P, Sheikh NA, Trager J, Drake CG
Immunotherapy is an important breakthrough in cancer. US Foo...
Development of a T Cell Receptor Mimic Antibody against Wild-Type p53 for Cancer Immunotherapy.
Cancer Res. 2017 Mar 31;:
Authors: Li D, Bentley C, Anderson A, Wiblin S, Cleary KL, Koustoulidou S, Hassanali T, Yates J, Greig J, Olde Nordkamp M, Trenevska I, Ternette N, Kessler BM, Corn...
Checkpoint Inhibitors: Common Immune-Related Adverse Events and Their Management.
Clin J Oncol Nurs. 2017 Apr 01;21(2):45-52
Authors: Gordon R, Kasler MK, Stasi K, Shames Y, Errante M, Ciccolini K, Skripnik Lucas A, Raasch P, Fischer-Cartlidge E
Cancer Immunotherapy: An Evidence-Based Overview and Implications for Practice.
Clin J Oncol Nurs. 2017 Apr 01;21(2):13-21
Authors: Bayer V, Amaya B, Baniewicz D, Callahan C, Marsh L, McCoy AS
BACKGROUND: Significant research progress has been made in immunother...
Molecular Pathways: Oncologic Pathways and Their Role in T-cell Exclusion and Immune Evasion- A New Role for the AXL Receptor Tyrosine Kinase.
Clin Cancer Res. 2017 Mar 13;:
Authors: Aguilera TA, Giaccia AJ
With the clinical impact of CTLA-4 and PD-1/PD-L1 immu...
Characterization of the anti-PD-1 antibody REGN2810 and its antitumor activity in human PD-1 knock-in mice.
Mol Cancer Ther. 2017 Mar 06;:
Authors: Burova E, Hermann A, Waite J, Potocky T, Lai V, Hong S, Liu M, Allbritton O, Woodruff A, Wu Q, D'Orvilliers A, Garnova E, Rafique A, Pouey...
Interplay between Immune Checkpoint Proteins and Cellular Metabolism.
Cancer Res. 2017 Feb 28;:
Authors: Lim S, Phillips JB, Madeira da Silva L, Zhou M, Fodstad O, Owen LB, Tan M
With the recent successes in immuno-oncology, renewed interest in the role of immu...
Heterogeneity in immune marker expression after acquisition of resistance to EGFR kinase inhibitors: analysis of a case with small cell lung cancer transformation.
J Thorac Oncol. 2017 Feb 10;:
Authors: Suda K, Murakami I, Yu H, Kim J, Ellison K, Rivard CJ, Mitsudomi T, Hirsch FR
Differential PI3Kδ signaling in CD4+ T cell subsets enables selective targeting of T regulatory cells to enhance cancer immunotherapy.
Cancer Res. 2017 Jan 20;:
Authors: Ahmad S, Abu-Eid R, Shrimali RK, Webb M, Verma V, Doroodchi A, Berrong Z, Samara RN, Rodriguez PC, Mkrtichyan M, Kh...
An immunogram for the cancer-immunity cycle: towards personalized immunotherapy of lung cancer.
J Thorac Oncol. 2017 Jan 11;:
Authors: Karasaki T, Nagayama K, Kuwano H, Nitadori JI, Sato M, Anraku M, Hosoi A, Matsushita H, Morishita Y, Kashiwabara K, Takazawa M, Ohara O, Kakimi K, Nak...
New White Paper - Immuno-Oncology: There's More To Discover